Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Objective</h3><p>Despite there is a wide range of antidepressants available, with various mechanisms of actions, the efficacy of current therapeutic options is yet satisfactory. Previous shreds of evidence have indicated that genetics, cognitive, neuroendocrine, as well as personality factors, are all intrinsically linked and contribute to the diversity of treatment outcomes. We, therefore, sought to investigate this hypothesis in this study.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Method</h3><p>Based on 610 samples treated with a selection of serotonin reuptake inhibitor (SSRI), serotonin-norepinephrine reuptake inhibitors (SNRI), noradrenergic and specific serotonergic antidepressant (NaSSA) or tricyclic antidepressant (TCA), we compared the therapeutic effects of these four classes of drugs by survival analyses. Pharmacogenomic and survival analyses were carried out to explore the hereditary factors for curative effect and the accumulation of genetic factors was further discussed through pathway analysis and the global test. We built a machine learning-based prediction model that integrates genetic and non-genetic factors (including cognition, endocrinology, personality intelligence) to distinguish drug efficacy in single class drug situations. The values of the non-genetic makers after 6 weeks' treatment were collected to evaluate the efficacy of the model.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3><p>Our results from the 6-week antidepressant therapeutic study indicated that SSRI and SNRI are better treatments than those of TCA and NaSSA in the Chinese population. Among all possible paired single-agent survival analyses, citalopram and venlafaxine were more effective than mirtazapine. Allele C carriers at rs6354 (<em>SLC6A4</em>) and allele G carriers at rs12150214 (<em>SLC6A4</em>) were significantly prone to poorer treatment response to fluoxetine. Besides, the combination of three loci (rs929377-rs6191-rs32897) located in HPA pathway was significantly associated with the treatment outcome of fluoxetine. In female MDD patients, the minor allele of rs6323 and rs1137070 on the <em>MAOA</em> gene likely lead to a worse response to venlafaxine. Furthermore, genetic variants linked to drug efficacy tended to concentrate on the neurotrophin pathway in depressed patients comorbid with anxiety. From multivariate models, more severe cognitive deficits, psychopathic personality and lower levels of operational intelligence, and higher levels of cortisol predicted worse response status with SSRI or SNRI after 6-week treatment. Notably, genetic factors in the multi-dimensional prediction model for both classes of drugs include loci in <em>HTR2A</em> and <em>CRHBP</em> genes.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusion</h3><p>SSRI and SNRI are more suitable for the treatment of Chinese people with depression. <em>SLC6A4</em> genetic variants, as well as HPA pathway, play an important role in the fluoxetine antidepressant therapeutic response while the polymorphism of <em>MAOA</em> gene involved in the pharmacological action of venlafaxine among female MDD patients. The presence of anxiety in MDD patients was related to the neurotrophin pathway. Genetic, cognitive, neuroendocrine, and personality intelligence factors combined have an ensemble impact on the medication effect of patients with major depression, leading to more precise and personalized medicine for specific groups of people.</p>

ABC Family Gene Polymorphisms and Cognitive Functions Interact to Influence Antidepressant Efficacy

Association Of Brain-Derived Neurotrophic Factor Genetic Val66met Polymorphism With Severity Of Depression, Efficacy Of Fluoxetine And Its Side Effects In Chinese Major Depressive Patients

ABCB6, ABCB1 and ABCG1 Genetic Polymorphisms and Antidepressant Response of SSRIs in Chinese Depressive Patients.

Influence of genetic polymorphisms in homocysteine and lipid metabolism systems on antidepressant drug response

Effect of ABCB1 gene polymorphisms on efficacy of antidepressants:a Meta-analysis

ABCB1 (MDR1) polymorphisms and antidepressant response in geriatric depression

ABCB1 Gene is Associated with Clinical Response to SNRIs in a Local Chinese Han Population.

Influence and interaction of genetic, cognitive, neuroendocrine and personalistic markers to antidepressant response in Chinese patients with major depression

Association of APC and REEP5 Gene Polymorphisms with Major Depression Disorder and Treatment Response to Antidepressants in a Han Chinese Population

ABCB1 variants and sex affect serotonin transporter occupancy in the brain

Results from a Portuguese Major Depressive Disorder Cohort

Analysis of the Deleterious Single-Nucleotide Polymorphisms Associated with Antidepressant Efficacy in Major Depressive Disorder

Influence of genetic polymorphisms involved in the hypothalamic-pituitary-adrenal axis and their interactions with environmental factors on antidepressant response.

Serotonin Transporter Gene: A New Polymorphism May Affect Response to Antidepressant Treatments in Major Depressive Disorder

Influence of methylenetetrahydrofolate reductase gene polymorphisms on antidepressant response]

[Association of TPH2 Gene Polymorphism with Response to Antidepressant Treatment among Ethnic Han Chinese Population].

Genetic variation in the tryptophan hydroxylase 2 gene moderates depressive symptom trajectories and remission over 8 weeks of escitalopram treatment.

Modification of the association between paroxetine serum concentration and SERT-occupancy by ABCB1 (P-glycoprotein) polymorphisms in major depressive disorder

Metabolic activity of CYP2C19 and CYP2D6 on antidepressant response from 13 clinical studies using genotype imputation: a meta-analysis

TPH, SLC6A2, SLC6A3, DRD2 and DRD4 Polymorphisms and Neuroendocrine Factors Predict SSRIs Treatment Outcome in the Chinese Population with Major Depression.